Home
About
Directors and Management
Careers
Corporate Governance
Board Charter
Code of Conduct
Audit Committee Charter
Nomination and Remuneration Committee Charter
Continuous Disclosure Policy
Share Trading Policy
Risk Management Policy
Social Media Policy
Performance Evaluation Process
Corporate Code of Conduct
Environmental, Social and Governance Statement
Whistleblower Policy
Investors
Public Disclosure Policy
ASX Announcements
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Financial Information & Reports
Share Registry Information
Analyst Coverage
Share Information
Anagenics in the media
Newsletter Archive
Contact
Shop évolis®
✕
Analyst Coverage
Home
Investor Centre
Analyst Coverage
Date
Analyst
Coverage x
05/10/2021
Pitt Street Research
Pitt Street Research – Cellmid Initiation Report
06/11/2019
Small Cap Insider
National Priceline Agreement
02/10/2019
Small Cap Insider
New Signed Distribution Agreements
30/08/2019
Small Cap Insider
Trending towards break even
29/05/2019
Small Cap Insider
New experienced midkine CEO appointment
13/09/2018
Blue Ocean Equities
Cellmid Limited Growth Trifecta. New Geographies. New Channels. New Products
24/01/2017
Next Biotech
CDY Backs Hair Raising Growth for 2017 as it Capitalises on US Entry
16/11/2016
Lodge Partners Research
Hair growth equals sales growth equals share price growth
10/10/2016
Switzer Super Report
Top commentator James Dunn from Switzer report rates CDY as a very interesting buy
27/06/2016
Van Leeuwenhoeck Research
Cellmid Valuation at AUD 0.086 per share
14/09/2015
Van Leeuwenhoeck Research
Cellmid Limited: Revenue stage biotech with strong pipeline
24/11/2014
Baillieu Holst Research
It’s rare for one company to own a whole new target this big
13/06/2014
Baillieu Holst Research
Australian Life Sciences
30/05/2014
Baillieu Holst Research
It’s rare for a company to own a whole new target this big
03/02/2014
Baillieu Holst Research and RM Research
First-in-Class mAb Oncology Program Will Rerate the Stock; Lots of Room to Grow for Advangen; New Target Price of 8.4c
11/03/2013
RM Research
Strong Investment Thesis Going Forward: Multiple Catalysts and Upside Opportunities – A Rare Find
15/10/2012
RM Research
Initiating Coverage
01/05/2011
Vista Partners
Initiates coverage on Cellmid Limited; AUD $0.10 Target Price…
01/11/2010
Wise-owl.com
Validated cancer diagnostic kit gives potential to enter US$45bn market…
18/04/2010
Wise-owl.com
A pivotal year for Cellmid…
18/10/2009
Wise-owl.com
Looking to profit from large IP portfolio…
15/05/2009
Wise-owl.com
Targeting the early detection of cancer…
Shop évolis®